alcw
2021-05-19
Zom zom
Could Zomedica Be a Millionaire-Maker Stock?
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":197110457,"tweetId":"197110457","gmtCreate":1621433012179,"gmtModify":1631892057644,"author":{"id":3555111166835926,"idStr":"3555111166835926","authorId":3555111166835926,"authorIdStr":"3555111166835926","name":"alcw","avatar":"https://static.tigerbbs.com/2a42015b779ee83338b8908f51124fd6","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Zom zom</p></body></html>","htmlText":"<html><head></head><body><p>Zom zom</p></body></html>","text":"Zom zom","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/197110457","repostId":2136911889,"repostType":2,"repost":{"id":"2136911889","kind":"highlight","pubTimestamp":1621422924,"share":"https://www.laohu8.com/m/news/2136911889?lang=&edition=full","pubTime":"2021-05-19 19:15","market":"us","language":"en","title":"Could Zomedica Be a Millionaire-Maker Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2136911889","media":"Motley Fool","summary":"Or will speculation lead to major disappointment?","content":"<p>At <a href=\"https://laohu8.com/S/AONE\">one</a> point in 2021, shares of <b>Zomedica Pharmaceuticals </b>(NYSEMKT:ZOM) were up more than 1,000% as it looked like the next big stock to own. The company, which focuses on pet health, has been a popular <a href=\"https://laohu8.com/S/AONE.U\">one</a> for retail investors to bet on. But in the past three months, its valuation has fallen sharply (more than 64%), while the <b>S&P 500</b> has remained up around 6% during the same period.</p>\n<p>With Zomedica's value down, is now the time to consider loading up on this pet healthcare stock, and will doing so make you a millionaire in the long run? Let's look at why it may or may not happen, and which scenario is the more likely one.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/896658fb5c1f3f6cfdcfc999b746956c\" tg-width=\"700\" tg-height=\"449\"><span>Image source: Getty Images.</span></p>\n<h2>Why Zomedica could make you a millionaire</h2>\n<p>The big hope for investors is that Zomedica's Truforma platform takes off and veterinarians across the country want to use it. The device helps diagnose and assess certain conditions, including hyperthyroidism. Right now, it's simply too early to tell how popular it will be; the company only made its first commercial sale of the device in March.</p>\n<p>The next several months could prove pivotal to demonstrate just how much demand there is for Truforma. And if Zomedica delivers a strong quarterly performance later this year, it wouldn't be surprising for the stock to not just reach the highs it hit earlier this year, but surpass them.</p>\n<p>One of the biggest wild cards for the stock is just how much hype it can generate, particularly among retail investors and speculators. It's that momentum that could drive the share price up several hundred percent if the company can give investors a reason to be bullish on its business.</p>\n<p>And there are signs that the company may be getting more aggressive in its growth strategy. On May 17, it announced the hiring of a vice president for business development to help \"lead acquisition and licensing efforts.\" From expanding product offerings to making investments, there are multiple areas the company looks to be focusing on. If it can diversify its operations and be less dependent on Truforma, that will go a long way in making this a more attractive stock to own.</p>\n<h2>Why it might not make you rich</h2>\n<p>The biggest reason Zomedica might not be a millionaire-maker stock is that the business has a long way to go in showing that it can generate strong sales numbers. And that's ultimately going to be tied to whether Truforma is successful or not.</p>\n<p>On May 12, Zomedica released its first-quarter results for the period ending March 31, and sales totaled just over $14,000. The company also incurred a loss of $4 million, which was 65% higher than the $2.5 million loss it reported a year ago. A key reason for that was that Zomedica's overhead has become more bloated -- selling, general, and administrative expenses of $3.5 million were double the prior-year amount. And with minimal revenue to offset the increase, that sent the company's financials deeper into the red.</p>\n<p>Even if its revenue increases and the bottom line improves, that may still not be enough to get investors buying up the stock again. Over the past few months, growth stocks have come under pressure, with investors rethinking the excessive multiples they have been paying for them. The <b>S&P 500</b> is now at a price-to-earnings (P/E) multiple of around 40, the highest it has been since the financial crisis of more than a decade ago. Sales multiples, meanwhile, are even higher:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5beae896ddffbd8f84526df0a0879436\" tg-width=\"720\" tg-height=\"387\"><span>S&P 500 P/E Ratio data by YCharts. TTM = trailing 12 months.</span></p>\n<p>A stock like Zomedica that is not just unprofitable, but generating minimal sales, could be among the hardest hit in a market correction.</p>\n<h2>Are you likely to make $1 million from investing in Zomedica?</h2>\n<p>It is possible that Zomedica could make you a millionaire -- it just isn't a scenario that I think is likely. If you were to invest $50,000 into the stock today and it were to get back to its 52-week high of $2.91, you would make a profit of nearly $140,000.For the investment to get to over $1 million, the stock would need to climb to more than $15. Over the long term, it's possible that could happen if everything goes just right for the business. But based on the information available today, there is too much uncertainty to say that's very likely.</p>\n<p>Zomedica is a stock that is only suitable for high-risk investors given its uncertain future, and it's an investment I'll personally be staying far away from.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Could Zomedica Be a Millionaire-Maker Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCould Zomedica Be a Millionaire-Maker Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-19 19:15 GMT+8 <a href=https://www.fool.com/investing/2021/05/19/could-zomedica-be-a-millionaire-maker-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At one point in 2021, shares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) were up more than 1,000% as it looked like the next big stock to own. The company, which focuses on pet health, has been a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/19/could-zomedica-be-a-millionaire-maker-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","UPRO":"三倍做多标普500ETF","ZOM":"Zomedica Pharmaceuticals Corp.","SH":"标普500反向ETF",".SPX":"S&P 500 Index","OEX":"标普100","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","SSO":"两倍做多标普500ETF","IVV":"标普500指数ETF","OEF":"标普100指数ETF-iShares"},"source_url":"https://www.fool.com/investing/2021/05/19/could-zomedica-be-a-millionaire-maker-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136911889","content_text":"At one point in 2021, shares of Zomedica Pharmaceuticals (NYSEMKT:ZOM) were up more than 1,000% as it looked like the next big stock to own. The company, which focuses on pet health, has been a popular one for retail investors to bet on. But in the past three months, its valuation has fallen sharply (more than 64%), while the S&P 500 has remained up around 6% during the same period.\nWith Zomedica's value down, is now the time to consider loading up on this pet healthcare stock, and will doing so make you a millionaire in the long run? Let's look at why it may or may not happen, and which scenario is the more likely one.\nImage source: Getty Images.\nWhy Zomedica could make you a millionaire\nThe big hope for investors is that Zomedica's Truforma platform takes off and veterinarians across the country want to use it. The device helps diagnose and assess certain conditions, including hyperthyroidism. Right now, it's simply too early to tell how popular it will be; the company only made its first commercial sale of the device in March.\nThe next several months could prove pivotal to demonstrate just how much demand there is for Truforma. And if Zomedica delivers a strong quarterly performance later this year, it wouldn't be surprising for the stock to not just reach the highs it hit earlier this year, but surpass them.\nOne of the biggest wild cards for the stock is just how much hype it can generate, particularly among retail investors and speculators. It's that momentum that could drive the share price up several hundred percent if the company can give investors a reason to be bullish on its business.\nAnd there are signs that the company may be getting more aggressive in its growth strategy. On May 17, it announced the hiring of a vice president for business development to help \"lead acquisition and licensing efforts.\" From expanding product offerings to making investments, there are multiple areas the company looks to be focusing on. If it can diversify its operations and be less dependent on Truforma, that will go a long way in making this a more attractive stock to own.\nWhy it might not make you rich\nThe biggest reason Zomedica might not be a millionaire-maker stock is that the business has a long way to go in showing that it can generate strong sales numbers. And that's ultimately going to be tied to whether Truforma is successful or not.\nOn May 12, Zomedica released its first-quarter results for the period ending March 31, and sales totaled just over $14,000. The company also incurred a loss of $4 million, which was 65% higher than the $2.5 million loss it reported a year ago. A key reason for that was that Zomedica's overhead has become more bloated -- selling, general, and administrative expenses of $3.5 million were double the prior-year amount. And with minimal revenue to offset the increase, that sent the company's financials deeper into the red.\nEven if its revenue increases and the bottom line improves, that may still not be enough to get investors buying up the stock again. Over the past few months, growth stocks have come under pressure, with investors rethinking the excessive multiples they have been paying for them. The S&P 500 is now at a price-to-earnings (P/E) multiple of around 40, the highest it has been since the financial crisis of more than a decade ago. Sales multiples, meanwhile, are even higher:\nS&P 500 P/E Ratio data by YCharts. TTM = trailing 12 months.\nA stock like Zomedica that is not just unprofitable, but generating minimal sales, could be among the hardest hit in a market correction.\nAre you likely to make $1 million from investing in Zomedica?\nIt is possible that Zomedica could make you a millionaire -- it just isn't a scenario that I think is likely. If you were to invest $50,000 into the stock today and it were to get back to its 52-week high of $2.91, you would make a profit of nearly $140,000.For the investment to get to over $1 million, the stock would need to climb to more than $15. Over the long term, it's possible that could happen if everything goes just right for the business. But based on the information available today, there is too much uncertainty to say that's very likely.\nZomedica is a stock that is only suitable for high-risk investors given its uncertain future, and it's an investment I'll personally be staying far away from.","news_type":1},"isVote":1,"tweetType":1,"viewCount":46,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/197110457"}
精彩评论